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Differential Expression of MT-I/II?
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ABSTRACT
In the central nervous system, zinc is released along with glutamate during neurotransmission and, in excess, 
can promote neuronal death. Experimental studies have shown that metallothioneins I/II (MT-I/II), which 
chelate free zinc, can affect seizures and reduce neuronal death after status epilepticus. Our aim was to evaluate 
the expression of MT-I/II in the hippocampus of patients with temporal lobe epilepsy (TLE). Hippocampi 
from patients with pharmacoresistant mesial temporal lobe epilepsy (MTLE) were evaluated for expression of 
MT-I/II and for neuronal, astroglial, and microglial populations. Compared to control cases, MTLE group 
displayed widespread increase in MT-I/II expression, astrogliosis and reduced neuronal population. MT-I/II 
levels did not correlate with any clinical variables, but patients with secondary generalized seizures (SGS) had 
less MT-I/II than patients without SGS. In conclusion, MT-I/II expression was increased in hippocampi from 
MTLE patients and our data suggest that it may be associated with different seizure spread patterns.
Keywords: Metallothioneins; zinc homeostasis; gliosis; epilepsy; neuronal density.
RESUMO
Níveis diferentes de MT-I/II entre pacientes com MTLE com ou sem crise generalizada: os níveis hipocampais de 
MT-I/II afetam o alastramento das crises, ou o alastramento das crises promove expressão diferencial de MT-I/II?
No sistema nervoso central, o zinco é liberado juntamente com o glutamato durante a neurotransmissão e, 
quando liberado em excesso, pode promover morte neuronal. Estudos indicam que as metalotioneínas I/II 
(MT-I/II), proteínas quelantes de zinco livre, podem afetar parâmetros relacionados às crises e reduzir a morte 
neuronal subsequente a um status epilepticus. Nosso objetivo foi avaliar a expressão de MT-I/II no hipocampo de 
pacientes com epilepsia do lobo temporal (ELT). Hipocampos de pacientes com ELT mesial (ELTM) resistente ao 
tratamento farmacológico foram avaliados para a expressão de MT-I/II e para as populações neuronal e astroglial. 
Quando comparadas com o grupo controle, pacientes com ELTM apresentaram aumento na expressão de 
MT-I/II, astrogliose e redução na densidade neuronal. Não foram observadas correlações entre os níveis de 
MT-I/II e as características clínicas dos pacientes, mas pacientes com crises secundariamente generalizadas 
apresentaram um aumento menor nos níveis de MT-I/II que os pacientes sem estas crises. Em resumo, um 
aumento na expressão de MT-I/II é observado em pacientes com ELTM e nossos dados sugerem que o aumento 
pode estar associado a diferentes padrões de crises epilépticas.
Unitermos: Metalotioneínas; homeostase do zinco; gliose; epilepsia; densidade neuronal.
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INTRODUCTION
Zinc (Zn2+) is an important modulator of glutamatergic 
transmission in the central nervous system (CNS).1-3 Zn2+ is 
concentrated in presynaptic vesicles, along with glutamate, 
and released during normal neurotransmission.4-8 
Hippocampal neurons are specially rich in vesicular 
Zn2+, particularly in the axonal boutons of granule 
cells, CA3 and CA1 pyramidal cells and prosubicular 
neurons.5-7,9,10 In temporal lobe epilepsy (TLE), one of 
the most frequent drug-resistant epilepsies in adults, the 
hippocampus is associated with seizure generation.11,12 
The intense neuronal activity during seizures can release 
high amounts of Zn2+ in the synaptic cleft,13,14 promoting 
reactive oxygen species (ROS) production,15 which can 
ultimately lead to hippocampal neuronal death.13-17 In fact, 
studies in hippocampi from TLE patients who underwent 
epilepsy surgery have shown neuronal loss,18-20 increased 
glial reaction21-24 and reorganization of mossy fibers axon 
collaterals into the inner molecular layer of the granule 
cell dendrites.19,25 This synaptic reorganization of Zn2+-
enriched terminals has been hypothesized to contribute to 
synchronous firing and epileptiform activity.19
Metallothioneins (MTs) are low molecular weight, 
cystein-enriched proteins that bound Zn2+ and cadmium. 
They can be found in various tissues, in four isoforms.26 
Isoforms I, II and III are found in the central nervous system 
(CNS), where the isoforms I and II are coexpressed in 
astrocytes and the isoform III is expressed in neurons.27,28 
MTs participate in Zn2+ homeostasis, scavenging ROS in the 
brain29 and stimulate the expression of several neurotrophic 
and antiinflamatory factors.30 Studies on rodent models of 
TLE have shown that MT expression is increased in the 
hippocampal formation shortly after seizures31,32 and that 
high levels of MTs I and II are associated with reduced 
neuronal death after seizure-induced damage.32-34
Since MT-I/II levels may be associated with neuron 
survival after seizures, we hypothesize that MT-I/II expression 
is altered in TLE and can be associated with the preservation 
of neuronal density in the hippocampus of TLE patients. 
Therefore, in this study we evaluated the immunoexpression 
of MT-I/II and its correlation with hippocampal neuron 
density in hippocampi of patients with chronic TLE.
MATERIALS AND METHODS
Patients and clinical data
Patients with drug-resistant epilepsy were evaluated 
at the University of São Paulo Epilepsy Surgical Centre in 
Ribeirão Preto (Brazil), according to standard protocols 
published elsewhere.35 MTLE patients (n=69) were patients 
with hippocampal atrophy or with normal hippocampal 
volume at MRI without other lesions associated with TLE.
For comparison purposes in the neuropathology studies, 
autopsy controls (Ctrl, n=20) were obtained from autopsy 
cases without history of neurological diseases, with no sign 
of CNS pathologies in post mortem pathological evaluation, 
and with less than 10 hours post mortem.
Medical records of all evaluated patients were assessed 
for clinical data analysis. The clinical variables investigated 
were age at death and cause of death for Ctrl patients and 
age at surgery, epilepsy duration, age at the first recurrent 
seizure, seizure frequency per month, presence of secondary 
generalized seizures, and neuropathological evaluation for 
MTLE patients. This study followed the principles of the 
Declaration of Helsinki, was registered in Brazilian’s Health 
Ministry and was approved by our local ethics committee 
(processes HCRP 9370/2003 and HCRP 2634/2008).
Tissue collection and immunohistochemistry
Hippocampi from surgery or autopsy were cut in 
coronal sections and placed in 10% (vol/vol) buffered 
formaldehyde for one week, followed by paraffin embedding. 
Immunohistochemistry was performed in 8 μm sections at 
the level of hippocampal body for evaluation of neuronal 
and astroglial populations and for MT-I/II expression with 
antibodies against, respectively, NeuN, GFAP and MT-I/II. 
The sections were submitted to endogenous peroxidase 
blocking with 4.5% H2O2 in 50 mM phosphate-saline 
buffer (PSB) pH 7.4, for 15 minutes, followed by microwave 
antigenic retrieval in 10mM sodium citrate buffer pH 6.0 (for 
GFAP) or 50 mM Tris-HCl pH 9.6 (for NeuN and MT-I/II). 
After achieving room temperature, the sections went 
through blocking free aldehyde groups with Tris-glycine 
0.1 M pH 7.4 for 45 minutes, followed by blocking buffer with 
5% defatted milk and 15% goat serum (# S-1000, Vector) in 
Triton buffer (PTB, 20mM phosphate + 0.45M NaCl, pH 
7.4, with 0.3% Triton X-100) for four hours. The sections 
were then incubated with primary antibodies in blocking 
buffer for 16 hours. We used primary monoclonal antibodies 
raised in mouse anti-human GFAP (clone 6F2, #M0761, 
Dako), anti-murine NeuN (clone A60, #MAB377, 
Chemicon) and anti-equine MT-I/II (clone E9, #M0639, 
Dako), diluted in blocking buffer at concentrations of 1:500. 
The primary antibodies were detected using biotinylated 
rabbit anti-murine IgG (#E0354, Dako), at 1:200 dilution 
in blocking buffer, for one hour, followed by revelation with 
avidin-biotin-peroxidase system (Vectastain Elite ABC kit, 
#PK6100, Vector) and diaminobenzidine as chromogen 
(DAB, #34001, Pierce Biotechnology). The development 
times in DAB solution were 10.5 minutes for NeuN and 
8 minutes for MT-I/II and GFAP.
Immunohistochemistry analysis
Images of all hippocampal regions were obtained with a 
video monochrome charge-coupled device camera (CCD; 
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Table 2. Neuronal density and percentage of immunopositive area for GFAP and MT-I/II in patients with MTLE and Ctrl
Region
NeuN* GFAP** MT-I/II**
MTLE Ctrl p MTLE Ctrl p MTLE Ctrl p
OML _ _ _ 59 4 < 0.001 46 10 < 0.001
IML 58 6 < 0.001 58±31 34±30 0.003
GCL 187.5 375 < 0.001 57±18 22±18 < 0.001 46±26 28±26 0.008
SGZ _ _ _ 90 69 < 0.001 48 11 < 0.001
HIL _ _ _ 86 28 < 0.001 30 7 < 0.001
CA4 9.0 35.9 < 0.001 72±22 18±21 < 0.001 30 12 0.031
CA3 19±11 47±6 < 0.001 60 6 < 0.001 55±28 27±28 < 0.001
CA2 29±9 41±4 < 0.001 52 5 < 0.001 62±25 30±29 < 0.001
CA1 4.5 41.9 < 0.001 87 2 < 0.001 66±28 31±31 < 0.001
PRO 19±8 32±3 < 0.001 78 1 < 0.001 64±29 34±32 < 0.001
SUB 30±6 35±3 0.029 23 0.2 < 0.001 66 31 < 0.001
* Neuronal density, as thousands of cells per cubic millimeter.
** Percentage of immunopositive area in the amostral area.
Hamamatsu Photonics Model 2400, Japan) attached to 
an Olympus microscope (Model BX60, Melville, NY), and 
captured, averaged, and digitized using a frame grabber 
(Scion Corporation, Frederick, MD) on a Macintosh 
computer (Model G3, Cupertino, CA). Illuminance was 
uniformly maintained and regularly checked using optical 
density standards (Kodak, Rochester, NY). After captured, 
the image was analyzed using image system software 
(ImageJ, version 1.37c).
Quantification of the immunohistochemistry was 
performed with threshold tool, with the investigator blind 
to the group allocation. After the selection of the region of 
interest (ROI), the software calculated the immunopositive 
area by counting all pixels with gray intensity equal or 
superior to the threshold of staining. A complete protocol 
for threshold tool can be found at rsbweb.nih.gov/ij/docs/
examples/stained-sections/index.html. The threshold was 
defined for each protein evaluated, based on the mean 
immunopositivity of all control cases. The evaluated 
regions were outer molecular layer (OML), inner molecular 
layer (IML), granule cell layer (GCL), subgranular zone 
(SGZ), the hilus (HIL) and the stratus piramidale of CA4, 
CA3, CA2, CA1, prosubiculum (PRO) and subiculum 
(SUB). The characterization of hippocampal regions was 
based on the Lorente de Nó’s classification.36 Results 
were shown as percentage of immunopositive area/total 
area.
Additionally, neuronal density was evaluated in the 
NeuN stained sections. Neuronal count was processed 
in ImageJ 1.37c software with a 520x magnification for 
granule cell layer and 260x for pyramidal neurons of 
CA4, CA3, CA2, CA1, prosubiculum and subiculum. 
Neuronal densities were estimated with the correction 
of Abercrombie37, which permits to estimate the 
neuronal density through mathematical method, and 
the results were shown as thousands of cells per cubic 
millimeter.
Statistical analysis
Statistics were carried out in SigmaStat 3.1 software. Tests 
for normality and homogeneity of variances were performed 
to define data distribution. For parametric variables, t-test 
was performed and, for the non-parametric variables, Mann-
Whitney test was used. Correlation between MT expression 
and clinical variables was performed using Pearson’s test. All 
results were considered significant at p<0.05.
RESULTS
Clinical data
The clinical characteristics of study participants are 
summarized in Table 1. Patients with MTLE and Ctrl 
patients have the same age (p=0.175). Epilepsy duration 
was 25±10 years, and the age at onset was 13±1. MTLE 
patients had seven seizures by month, being one of those a 
secondary generalized seizure (SGS). 
Table 1. Clinical history of patients with MTLE and Ctrl cases
Group Ctrl MTLE
Age at evaluation* (years) 42±16 38±10
Epilepsy duration (years) _ 25±10
Age at epilepsy onset (years) _ 13±1
Minimal seizure frequency (per month) _ 7
Number of secondary generalizations (per month) _ 1
Frequency of secondary generalization (%) _ 59
* Age of death for Ctrl and age at surgery for TLE.
Immunohistochemistry evaluation
Neuronal density, estimated with the count of NeuN 
positive cells, was reduced in the granule cell layer, CA4, 
CA3, CA2, CA1, prosubiculum and subiculum of the 
MTLE group, when compared to Ctrl (p < 0.03). Increased 
astrogliosis was observed in all hippocampal regions of MTLE, 
compared to Ctrl (p < 0.001). MT-I/II expression, observed in 
astrocyte-like cells, was increased in all hippocampal subfields 
evaluated (p < 0.032). For further details, see Table 2.
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The results are shown as median (for Mann Whitney 
test) or mean ± standard deviation (for Student’s t-test). 
OML = outer molecular layer; IML = inner molecular 
layer; GCL = granule cell layer; SGZ = subgranule zone; 
HIL = hilus; PRO = prosubiculum; SUB = subiculum.
Tissue alterations and seizures
In MTLE group, patients without SGS had increased 
MT-I/II immunopositivity, when compared with patients 
with SGS, in the inner molecular layer (p=0.037), granule 
cell layer (p=0.018), subgranule zone (p=0.004), CA2 
(p=0.039) and CA1 (p<0.043). A trend to increased 
MT-I/II immunopositivity was observed in the outer 
molecular layer (p=0.072), CA4 (p=0.076) and subiculum 
(p=0.068). No differences in neuronal or astroglial 
populations were observed between MTLE patients with 
or without SGS. Frequency of seizures did not correlate 
with NeuN, GFAP or MT-I/II in all hippocampal subfields.
DISCUSSION
In the present study, we found an increased MT-I/II 
expression in all hippocampal subfields of MTLE patients. 
In the CNS, MT-I/II are expressed mainly by astrocytes38 
and, when the tissue suffers an injury, increased MT-I/II 
expression is observed in astrocytes and microglias.28,38 
We also observed that higher degree of MT-I/II expression 
was observed in regions with higher astrogliosis. Increased 
glial population is a common finding in TLE21-24 and is 
associated with the degree of neuronal death.22-24,39 In our 
study, an increased expression of MT-I/II was observed in 
astrocytes and in a few neurons of some patients. Thus, our 
data support the notion that MT-I/II changes are essentially 
related to astroglial population.
Studies in rodents with kainic acid-induced SE showed 
an association between MT-I/II expression and neuronal 
protection. Transgenic mice over-expressing MT-I/II have 
reduced neuronal death, compared to wild type animals.34 
In addition, mice with reduced MT-I/II expression32 or 
knockouts for MT-I/II33 had increased neuronal death 
following SE, compared to wild type mice. In our study, 
however, the higher MT-I/II expression was observed in 
regions with lower neuronal density, indicating that MT-I/II 
was not associated with neuronal survival. In agreement with 
our data, an association between the severity of tissue damage 
and the increase in MT-I/II expression has been reported in 
mice subjected to soman-induced status epilepticus (SE).31
Data have shown that the increased MT-I/II 
immunoreactivity observed in animal models of TLE can 
also be a factor associated with the seizure generation 
process. Transgenic mice over-expressing MT-I, have 
increased seizure duration, a tendency to reduced latency, 
but similar number of seizures after KA administration.34 
Since MT-I/II act chelating free Zn2+14,27 and Zn2+ 
chelation  increases tissue excitability and facilitates seizure 
generation40, excessive MT-I/II levels can reduce free Zn2+ 
in the synaptic cleft, increasing neuronal excitability and 
affecting seizure generation. We found no correlation 
between seizure frequency and MT-I/II expression in TLE.34
In MTLE, we found increased levels of MT-I/II in 
patients without SGS, when compared with those with SGS. 
This could indicate that MT-I/II is associated with different 
seizure spread patterns from the epileptogenic hippocampus 
to other brain regions. It is important to point out that no 
difference in neurons or glial cells was observed between 
MTLE with and without SGS. Studies from different 
groups also observed no association between changes in 
the hippocampus and SGS.41-43 All those observations 
suggest that the increased MT-I/II expression in patients 
without SGS is not an effect of gliosis, but it is independently 
associated with SGS. Further studies with animal models of 
TLE must evaluate more closely the relationship between 
MT-I/II expression and seizure susceptibility.
Some limitations of our study must be pointed out. 
So far, studies about MT-I/II expression in animal models 
of TLE only evaluated the acute period following SE. 
Considering that our study was performed in patients with 
chronic epilepsy, it is difficult to establish comparisons 
between human and animal data. The lack of correlation 
between seizure frequency and MT-I/II expression does 
not exclude an association between seizures and MT-I/II 
expression. Other seizure characteristics, such as seizure 
duration and time between the last seizure and the surgery, 
could better correlate with MT-I/II expression than isolate 
seizure frequency.
Finally, our study may have translational implications 
in the future. The role of MTs in antiinflamatory response, 
neurotrophic factor expression, and protection against 
ROS and heavy metals make those proteins interesting 
for clinical applications. Studies have shown that 
EmtinB, a syntethic peptide that mimics the actions 
of MTs, attenuates KA-induced seizures and protects 
neurons from excitotoxic death.30 Further studies with 
EmtinB and MTs should be done to evaluate the role of 
these proteins in neuronal survival and seizure susceptibility.
In summary, our data indicate that increased MT-I/II 
expression is a plastic alteration of chronic TLE, primarily 
related to the astrogliosis, a common finding in chronic 
TLE. Our findings suggest that increase MT-I/II expression 
may contribute to the control of the brain hyperexcitability.
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